Chinook Therapeutics, Inc. (KDNY)

Market Cap	1.57B
Revenue (ttm)	56.85M
Net Income (ttm)	-117.77M
Shares Out	63.94M
EPS (ttm)	-1.70
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	80,553
Open	25.18
Previous Close	25.27
Day's Range	24.30 - 25.48
52-Week Range	11.81 - 27.44
Beta	0.36
Analysts	Buy
Price Target	37.17 (+51.47%)
Earnings Date	Mar 16, 2023

About KDNY

Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the t...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Stephen Isaacs
• Employees: 138
• Stock Exchange: NASDAQ
• Ticker Symbol: KDNY

Financial Performance

In 2021, KDNY's revenue was $51.63 million, an increase of 6142.44% compared to the previous year's $827,000. Losses were -$102.94 million, 26.1% more than in 2020.

Analyst Forecast

According to 16 analysts, the average rating for KDNY stock is "Buy." The 12-month stock price forecast is $37.17, which is an increase of 51.47% from the latest price.

Price Target

$37.17

(51.47% upside)

Analyst Consensus: Buy